{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:12:06Z","timestamp":1787497926745,"version":"build-2736575974"},"reference-count":24,"publisher":"Impact Journals, LLC","issue":"102","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,12,28]]},"DOI":"10.18632\/oncotarget.26514","type":"journal-article","created":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T11:22:06Z","timestamp":1545996126000},"page":"37753-37765","source":"Crossref","is-referenced-by-count":9,"title":["Targeting protein kinase CK2 and CDK4\/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia"],"prefix":"10.18632","volume":"9","author":[{"given":"Amol","family":"Padgaonkar","sequence":"first","affiliation":[{"name":"Department of Oncological Sciences, Icahn School of Medicine, New York 10029, NY, USA"},{"name":"Present Address: Prescient Healthcare Group, Jersey City 07302, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Rechkoblit","sequence":"additional","affiliation":[{"name":"Department of Pharmacological Sciences, Icahn School of Medicine, New York 10029, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodgrigo","family":"Vasquez-Del Carpio","sequence":"additional","affiliation":[{"name":"Department of Oncological Sciences, Icahn School of Medicine, New York 10029, NY, USA"},{"name":"Present address: Sandoz, a Novartis Company, Miami 33126, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkat","family":"Pallela","sequence":"additional","affiliation":[{"name":"Present address: Pfizer, Collegeville 19426, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata","family":"Subbaiah DRC","sequence":"additional","affiliation":[{"name":"Department of Oncological Sciences, Icahn School of Medicine, New York 10029, NY, USA"},{"name":"Present address: Carnegie Pharmaceuticals, Monmouth Junction 08852, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Cosenza","sequence":"additional","affiliation":[{"name":"Department of Oncological Sciences, Icahn School of Medicine, New York 10029, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey J.","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Oncological Sciences, Icahn School of Medicine, New York 10029, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.V. Ramana","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Oncological Sciences, Icahn School of Medicine, New York 10029, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneel","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Pharmacological Sciences, Icahn School of Medicine, New York 10029, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Premkumar","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Oncological Sciences, Icahn School of Medicine, New York 10029, NY, USA"},{"name":"Department of Pharmacological Sciences, Icahn School of Medicine, New York 10029, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,12,28]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.V69.6.1617.1617","article-title":"Intermediate lymphocytic lymphoma: immunophenotypic and cytogenetic findings","volume":"69","author":"Purtilo","year":"1987","journal-title":"Blood"},{"key":"2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1365-2141.1992.tb08209.x","article-title":"Chromosome 11q rearrangements in B non-Hodgkin's lymphoma","volume":"81","author":"Mecucci","year":"1992","journal-title":"Br J Haematol"},{"key":"3","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1182\/blood.V84.8.2726.2726","article-title":"PRAD-1\/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma","volume":"84","author":"Rozman","year":"1994","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Hurt","year":"2003","journal-title":"Cancer Cell"},{"key":"5","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1158\/1078-0432.CCR-14-0836","article-title":"New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature?","volume":"20","author":"Klapper","year":"2014","journal-title":"Clin Cancer Res"},{"key":"6","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1177\/1947601913478972","article-title":"CDK4: A Key Player in the Cell Cycle, Development, and Cancer","volume":"3","author":"Reddy","year":"2012","journal-title":"Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1182\/blood-2006-04-016634","article-title":"Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity","volume":"108","author":"Wasik","year":"2006","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Raffeld","year":"2006","journal-title":"Blood"},{"key":"9","doi-asserted-by":"publisher","first-page":"6544","DOI":"10.18632\/oncotarget.3446","article-title":"Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth","volume":"6","author":"Pileri","year":"2015","journal-title":"Oncotarget"},{"key":"10","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Look","year":"2008","journal-title":"Lancet"},{"key":"11","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1172\/JCI61269","article-title":"The molecular basis of T cell acute lymphoblastic leukemia","volume":"122","author":"Ferrando","year":"2012","journal-title":"J Clin Invest"},{"key":"12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1074\/jbc.M009134200","article-title":"The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation","volume":"276","author":"Pulido","year":"2001","journal-title":"J Biol Chem"},{"key":"13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1535-6108(03)00301-5","article-title":"Requirement for cyclin D3 in lymphocyte development and T cell leukemias","volume":"4","author":"Sicinski","year":"2003","journal-title":"Cancer Cell"},{"key":"14","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ccr.2012.09.015","article-title":"The requirement for cyclin D function in tumor maintenance","volume":"22","author":"Sicinski","year":"2012","journal-title":"Cancer Cell"},{"key":"15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ccr.2012.09.016","article-title":"Therapeutic targeting of the cyclin D3: CDK4\/6 complex in T cell leukemia","volume":"22","author":"Aifantis","year":"2012","journal-title":"Cancer Cell"},{"key":"16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/ncomms1093","article-title":"Protein-binding assays in biological liquids using microscale thermophoresis","volume":"1","author":"Duhr","year":"2010","journal-title":"Nat Commun"},{"key":"17","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1021\/jm0600388","article-title":"Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition","volume":"49","author":"Schulze-Gahmen","year":"2006","journal-title":"J Med Chem"},{"key":"18","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1172\/JCI34616","article-title":"PTEN posttranslational inactivation and hyperactivation of the PI3K\/Akt pathway sustain primary T cell leukemia viability","volume":"118","author":"Barata","year":"2008","journal-title":"J Clin Invest"},{"key":"19","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/sj.cdd.4401604","article-title":"Protein kinase CK2 phosphorylates and upregulates Akt\/PKB","volume":"12","author":"Ruzzene","year":"2005","journal-title":"Cell Death Differ"},{"key":"20","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","article-title":"Cyclin-dependent kinase pathway s as targets for cancer treatment","volume":"24","author":"Shapiro","year":"2006","journal-title":"J Clin Oncol"},{"key":"21","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","article-title":"Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts","volume":"3","author":"Toogood","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"22","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1021\/jm049354h","article-title":"Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4\/6","volume":"48","author":"Fry","year":"2005","journal-title":"J Med Chem"},{"key":"23","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Millenson","year":"2012","journal-title":"Blood"},{"key":"24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1089\/adt.2011.0380","article-title":"Molecular interaction studies using microscale thermophoresis","volume":"9","author":"Duhr","year":"2011","journal-title":"Assay Drug Dev Technol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.26514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T02:21:40Z","timestamp":1662690100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.26514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,28]]},"references-count":24,"journal-issue":{"issue":"102","published-print":{"date-parts":[[2018,12,28]]}},"alternative-id":["26514","30701029"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.26514","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,28]]}}}